Injectable Bioactive Composites vs RMGI for Proximal Cavities in Primary Molars
ConditionDental Caries
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3-8
SponsorCairo University
About this trial
This randomized clinical trial aims to evaluate and compare the clinical performance of injectable bioactive composite (Beautifil Flow Plus X, Shofu) versus Resin Modified Glass Ionomer (RMGI) in restoring proximal cavities (Class II) in primary molars of children aged 3-8 years over a 12-month follow-up period, using revised FDI criteria.
Eligibility criteria
Qualifiers
Children aged 3-8 years of both genders
Cooperative behavior manageable by operators
Willing to sign informed consent
Accepts the follow-up period
Disqualifiers
Allergy to any restorative materials
Patients undergoing orthodontic treatment with fixed appliances
Patients with debilitating systemic diseases
Children with special needs
Trial design
Treatments tested in this trial
- giomer
- RMGI
Treatment groups
50 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov